Investing.com - Lucid Diagnostics (NASDAQ: LUCD) reported second quarter EPS of $-0.23, $0.05 better than the analyst estimate of $-0.28. Revenue for the quarter came in at $159K versus the consensus estimate of $620K.
Lucid Diagnostics's stock price closed at $1.49. It is down -5.70% in the last 3 months and down -54.57% in the last 12 months.
Lucid Diagnostics saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Lucid Diagnostics's stock price’s past reactions to earnings here.
According to InvestingPro, Lucid Diagnostics's Financial Health score is "weak performance".
Check out Lucid Diagnostics's recent earnings performance, and Lucid Diagnostics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar